Research

Hormonal

Antiandrogen treatment with spironolactone (SP) in obese postmenopausal women undergoing weight loss results in a smaller loss of subcutaneous abdominal fat compared to placebo, with no significant improvement in visceral fat loss.

Taking spironolactone (75mg daily) during weight loss does not appear to offer any advantage in fat loss or body composition for obese postmenopausal women compared to diet alone. It may even result in less total fat loss.

GoodRefutesHIGH confidence
The SP group lost fat at 3 months, but by 9 months had regained it so that, in total, they lost significantly less body fat than the PL and ND groups... The SP group had significantly more SC fat than the ND group at 9 months
Jennifer C. Lovejoy et al. · The Journal of Clinical Endocrinology & Metabolism · 1996

Why this rating

Randomized, placebo-controlled clinical trial.

Source

Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women--a clinical research center study.

Jennifer C. Lovejoy et al. · The Journal of Clinical Endocrinology & Metabolism · 1996

DOI 10.1210/jcem.81.6.8964851

rct · n=30Cited 203×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →